Safety, tolerability, and efficacy of orally administered cannabinoids in MS
J Killestein, ELJ Hoogervorst, M Reif, NF Kalkers… - Neurology, 2002 - AAN Enterprises
J Killestein, ELJ Hoogervorst, M Reif, NF Kalkers, AC Van Loenen, PGM Staats, RW Gorter…
Neurology, 2002•AAN EnterprisesThe authors conducted a randomized, double-blind, placebo-controlled, twofold crossover
study in 16 patients with MS who presented with severe spasticity to investigate safety,
tolerability, and efficacy of oral Δ9-Tetrahydrocannabinol (THC) and Cannabis sativa plant
extract. Both drugs were safe, but adverse events were more common with plant-extract
treatment. Compared with placebo, neither THC nor plant-extract treatment reduced
spasticity. Both THC and plant-extract treatment worsened the participant's global …
study in 16 patients with MS who presented with severe spasticity to investigate safety,
tolerability, and efficacy of oral Δ9-Tetrahydrocannabinol (THC) and Cannabis sativa plant
extract. Both drugs were safe, but adverse events were more common with plant-extract
treatment. Compared with placebo, neither THC nor plant-extract treatment reduced
spasticity. Both THC and plant-extract treatment worsened the participant's global …
The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Δ9-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant’s global impression.
American Academy of Neurology